scholarly journals In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

2004 ◽  
Vol 48 (4) ◽  
pp. 1384-1396 ◽  
Author(s):  
Yigong Ge ◽  
Matthew A. Wikler ◽  
Daniel F. Sahm ◽  
Renée S. Blosser-Middleton ◽  
James A. Karlowsky

ABSTRACT The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 μg/ml for 10 species of Enterobacteriaceae (n = 351), from 0.03 to 0.12 μg/ml for oxacillin-susceptible staphylococci (n = 119), from 4 to 32 μg/ml for oxacillin-resistant staphylococci (n = 64), from ≤0.008 to 0.06 μg/ml for penicillin-susceptible streptococci (n = 132), and from 1 to 4 μg/ml for penicillin-resistant streptococci (n = 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.

2005 ◽  
Vol 49 (8) ◽  
pp. 3501-3512 ◽  
Author(s):  
Helio S. Sader ◽  
Thomas R. Fritsche ◽  
Koné Kaniga ◽  
Yigong Ge ◽  
Ronald N. Jones

ABSTRACT PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.


2006 ◽  
Vol 50 (6) ◽  
pp. 2261-2264 ◽  
Author(s):  
Hee-Soo Park ◽  
Hyun-Joo Kim ◽  
Min-Jung Seol ◽  
Dong-Rack Choi ◽  
Eung-Chil Choi ◽  
...  

ABSTRACT DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.


Author(s):  
Meredith A. Hackel ◽  
James A. Karlowsky ◽  
Michele A. Canino ◽  
Daniel F. Sahm ◽  
Nicole E. Scangarella-Oman

Gepotidacin (formerly GSK2140944) is a first in class triazaacenaphthylene antibacterial currently in Phase III clinical trials. When tested against Gram-negative ( n =333) and Gram-positive ( n =225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates (MIC 90 ) at concentrations of 4 and 2 μg/ml, respectively. Given gepotidacin’s in vitro activity against the anaerobic isolates tested, further study is warranted to better understand gepotidacin’s utility in the treatment of infections caused by clinically relevant anaerobic organisms.


2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  

Chemotherapy ◽  
2007 ◽  
Vol 54 (1) ◽  
pp. 43-49 ◽  
Author(s):  
S. Roveta ◽  
A. Marchese ◽  
E.A. Debbia

Sign in / Sign up

Export Citation Format

Share Document